Literature DB >> 18698687

Vanishing bile duct and Stevens-Johnson syndrome associated with ciprofloxacin treated with tacrolimus.

Gokhan Okan1, Serpil Yaylaci, Onder Peker, Sabahattin Kaymakoglu, Murat Saruc.   

Abstract

Stevens-Johnson syndrome (SJS) is a serious and potentially life-threatening disease. Vanishing bile duct syndrome (VBDS) is a rare cause of progressive cholestasis. Both syndromes are mostly related with drugs. We report a case of a patient with ciprofloxacin-induced SJS and acute onset of VBDS, and reviewed the related literature. It is the first case of ciprofloxacin-induced VBDS successfully treated with tacrolimus. This case reminds physicians of the importance of drug reactions, their severity, techniques for diagnosis and methods of management.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18698687      PMCID: PMC2738797          DOI: 10.3748/wjg.14.4697

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  16 in total

1.  Stevens-Johnson syndrome induced by doxycycline.

Authors:  Natalie N Cac; Michael J Messingham; Patrick J Sniezek; Hobart W Walling
Journal:  Cutis       Date:  2007-02

2.  Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese.

Authors:  Celeste B L Man; Patrick Kwan; Larry Baum; Evelyn Yu; K M Lau; Alice S H Cheng; Margaret H L Ng
Journal:  Epilepsia       Date:  2007-05       Impact factor: 5.864

3.  Pharmacogenomic biomarkers for prediction of severe adverse drug reactions.

Authors:  Magnus Ingelman-Sundberg
Journal:  N Engl J Med       Date:  2008-02-07       Impact factor: 91.245

Review 4.  Stevens-Johnson Syndrome and cholestatic hepatitis.

Authors:  M S Morelli; F X O'Brien
Journal:  Dig Dis Sci       Date:  2001-11       Impact factor: 3.199

5.  Detection of an autoantibody directed against human liver microsomal protein in a patient with carbamazepine hypersensitivity.

Authors:  M Pirmohamed; N R Kitteringham; A M Breckenridge; B K Park
Journal:  Br J Clin Pharmacol       Date:  1992-02       Impact factor: 4.335

6.  Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis.

Authors:  M Caproni; D Torchia; E Schincaglia; W Volpi; A Frezzolini; D Schena; A Marzano; P Quaglino; C De Simone; A Parodi; E Barletta; P Fabbri
Journal:  Br J Dermatol       Date:  2006-10       Impact factor: 9.302

7.  Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.

Authors:  J C Roujeau; J P Kelly; L Naldi; B Rzany; R S Stern; T Anderson; A Auquier; S Bastuji-Garin; O Correia; F Locati
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

8.  Drug-associated acute-onset vanishing bile duct and Stevens-Johnson syndromes in a child.

Authors:  M Srivastava; A Perez-Atayde; M M Jonas
Journal:  Gastroenterology       Date:  1998-09       Impact factor: 22.682

Review 9.  Stevens-Johnson syndrome associated with ciprofloxacin: a review of adverse cutaneous events reported in Sweden as associated with this drug.

Authors:  Jenny Hällgren; Maria Tengvall-Linder; Matty Persson; Carl-Fredrik Wahlgren
Journal:  J Am Acad Dermatol       Date:  2003-11       Impact factor: 11.527

Review 10.  Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.

Authors:  Gustav Paumgartner; Ulrich Beuers
Journal:  Hepatology       Date:  2002-09       Impact factor: 17.425

View more
  10 in total

Review 1.  Drug-induced cholestasis.

Authors:  Manmeet S Padda; Mayra Sanchez; Abbasi J Akhtar; James L Boyer
Journal:  Hepatology       Date:  2011-04       Impact factor: 17.425

2.  Successful Treatment of Stevens-Johnson Syndrome with Cyclosporine and Corticosteroid.

Authors:  Jessica Auyeung; Monica Lee
Journal:  Can J Hosp Pharm       Date:  2018-08-28

Review 3.  Infliximab/Plasmapheresis in vanishing bile duct syndrome secondary to toxic epidermal necrolysis.

Authors:  Jason C White; Stephanie Appleman
Journal:  Pediatrics       Date:  2014-09-22       Impact factor: 7.124

4.  Tacrolimus (FK506): Safety and Applications in Reconstructive Surgery.

Authors:  Thomas H Tung
Journal:  Hand (N Y)       Date:  2009-04-11

Review 5.  Fluoroquinolone-induced liver injury: three new cases and a review of the literature.

Authors:  Anna Licata; Claudia Randazzo; Ilaria Morreale; Giuseppe Butera; Natale D'Alessandro; Antonio Craxì
Journal:  Eur J Clin Pharmacol       Date:  2012-01-14       Impact factor: 3.064

Review 6.  Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Authors:  Marianne Lerch; Carlo Mainetti; Benedetta Terziroli Beretta-Piccoli; Thomas Harr
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 10.817

7.  Culprit Medications and Risk Factors Associated with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Population-Based Nested Case-Control Study.

Authors:  Naomi Gronich; David Maman; Nili Stein; Walid Saliba
Journal:  Am J Clin Dermatol       Date:  2022-02-04       Impact factor: 6.233

8.  Ibuprofen associated acute vanishing bile duct syndrome and toxic epidermal necrolysis in an infant.

Authors:  Hye-young Kim; Hea Kyoung Yang; Seong Heon Kim; Jae Hong Park
Journal:  Yonsei Med J       Date:  2014-04-01       Impact factor: 2.759

9.  Infliximab-Induced Vanishing Bile Duct Syndrome.

Authors:  Michael J Eiswerth; Matthew A Heckroth; Ali Ismail; Dibson D Gondim; Ryan Kaufman
Journal:  Cureus       Date:  2022-02-05

10.  Successful liver transplantation for drug-induced vanishing bile duct syndrome.

Authors:  Ahmed Hashim; Ashley Barnabas; Rosa Miquel; Kosh Agarwal
Journal:  BMJ Case Rep       Date:  2020-01-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.